Categories

I-CARE Early Covid (3) I-CARE Flu and RSV (1) I-PREVENT (28) I-RECOVER Long Covid (3) I-RECOVER Post-Vaccine (3) MATH+ (20)

Tags

25-hydroxyvitamin D (2) 25‐HYDROXY VITAMIN D (2) Ambulatory treatment (2) Anti-inflammatory (2) Anti-Inflammatory Agents (1) Anticoagulant (2) Antimicrobial Cationic Peptides (1) Antiparasitic Agents (3) Antiviral (2) Ascorbic Acid (3) Calcifediol (1) Collagen (1) Coronavirus (2) COVID-19 (23) Dithiothreitol (1) Endothelial Barrier (1) Endothelial Permeability (1) Epidemiology (2) Ergocalciferols (1) Famotidine (7) Fixed drug eruption (1) Glucocorticosteroids (3) Heparanase (2) Human immunodeficiency virus (HIV) (1) Hydroxychloroquine (2) Inflammation (4) ivermectin (18) Melatonin (13) Methylprednisol (2) Nitric Oxide (1) Omicron (6) Onchocerciasis (1) pharmacokinetics (1) Pneumonia (2) SARS-CoV-2 (20) Sars-CoV2 (2) Sepsis (3) Septic (2) Spike Protein (5) Stevens–Johnson syndrome (SJS) (1) Tempol (1) viral infection (3) Vitamin C (3) Vitamin D (6) vitamin D 2 (1)

  • Reference: Epidemiological characterization of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021

    Published On: December 16, 2021

    By 9 December 2021, 785 SARS-CoV-2 Omicron variant cases have been identified in Denmark. Most cases were fully (76%) or booster-vaccinated (7.1%); 34 (4.3%) had a previous SARS-CoV-2 infection. The majority of cases with available information reported symptoms (509/666; 76%) and most were infected in Denmark (588/644; 91%).

    Categories:

    Tags: COVID-19, Denmark, Epidemiology, Omicron, SARS-CoV-2